SG155901A1 - Enzyme inhibitors and uses thereof - Google Patents

Enzyme inhibitors and uses thereof

Info

Publication number
SG155901A1
SG155901A1 SG200905965-0A SG2009059650A SG155901A1 SG 155901 A1 SG155901 A1 SG 155901A1 SG 2009059650 A SG2009059650 A SG 2009059650A SG 155901 A1 SG155901 A1 SG 155901A1
Authority
SG
Singapore
Prior art keywords
inhibitors
present
irap
enzyme inhibitors
lactation
Prior art date
Application number
SG200905965-0A
Other languages
English (en)
Inventor
Siew Yeen Chai
Michael William Parker
Anthony Lloyd Albiston
Craig J Morton
Hooi Ling Ng
Siying Ye
Frederick A O Mendelsohn
Original Assignee
Florey Howard Inst
St Vincentaes Inst Of Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004905182A external-priority patent/AU2004905182A0/en
Application filed by Florey Howard Inst, St Vincentaes Inst Of Medical filed Critical Florey Howard Inst
Publication of SG155901A1 publication Critical patent/SG155901A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200905965-0A 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof SG155901A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2004905182A AU2004905182A0 (en) 2004-09-09 Enzyme inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
SG155901A1 true SG155901A1 (en) 2009-10-29

Family

ID=36036029

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905965-0A SG155901A1 (en) 2004-09-09 2005-09-09 Enzyme inhibitors and uses thereof

Country Status (13)

Country Link
US (1) US20080194636A1 (ja)
EP (1) EP1789079B1 (ja)
JP (1) JP5031567B2 (ja)
KR (1) KR20070100878A (ja)
CN (1) CN101039690A (ja)
CA (1) CA2579768A1 (ja)
DK (1) DK1789079T3 (ja)
ES (1) ES2403340T3 (ja)
IL (1) IL181819A (ja)
NZ (1) NZ553688A (ja)
SG (1) SG155901A1 (ja)
WO (1) WO2006026832A1 (ja)
ZA (1) ZA200702041B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ585338A (en) 2007-11-19 2012-08-31 Howard Florey Inst Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof
CN101284820B (zh) * 2008-04-25 2011-05-04 南昌大学 一种氨肽酶抑制剂及合成方法
CN103848805A (zh) * 2012-12-06 2014-06-11 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103896900A (zh) * 2012-12-25 2014-07-02 韩冰 一类具有神经保护作用的化合物及其制备方法和用途
EP3150581B1 (en) 2014-05-28 2020-04-15 Astellas Pharma Inc. Pyridine derivative
AR102849A1 (es) 2015-03-09 2017-03-29 Astellas Pharma Inc Compuesto de piridina bicíclica
EP3328384B1 (en) 2015-07-30 2020-07-29 Monash University Fibrotic treatment
WO2023099589A1 (en) 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Irap inhibitors for use in the treatment of inflammatory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284868A (en) * 1991-10-09 1994-02-08 Eli Lilly And Company Pharmaceutical compounds
US5281619A (en) * 1992-09-25 1994-01-25 Eli Lilly And Company Therapy for diabetic complications
EP0599514A3 (en) 1992-11-18 1994-07-06 Lilly Industries Ltd Pyranoquinoline derivatives as inhibitors of cell proliferation.
US6680332B1 (en) * 1999-06-04 2004-01-20 Euro-Celtique S.A. Substituted 5-oxo-5,6,7,8-tetrahydro-4H-1-benzopyrans and benzothiopyrans and the use thereof as potentiators of AMPA
ATE450531T1 (de) * 2001-05-16 2009-12-15 Cytovia Inc Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel
EP1420800B1 (en) * 2001-08-02 2011-09-28 Howard Florey Institute Of Experimental Physiology And Medicine Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
ATE309988T1 (de) * 2002-02-13 2005-12-15 Hoffmann La Roche Neue pyridin- und quinolin-derivate
NZ585338A (en) * 2007-11-19 2012-08-31 Howard Florey Inst Insulin-regulated aminopeptidase (irap) inhibitors and uses thereof

Also Published As

Publication number Publication date
WO2006026832A1 (en) 2006-03-16
NZ553688A (en) 2011-05-27
EP1789079A4 (en) 2010-09-01
ES2403340T3 (es) 2013-05-17
DK1789079T3 (da) 2013-03-11
JP2008512395A (ja) 2008-04-24
CA2579768A1 (en) 2006-03-16
KR20070100878A (ko) 2007-10-12
IL181819A (en) 2013-07-31
IL181819A0 (en) 2007-07-04
CN101039690A (zh) 2007-09-19
EP1789079A1 (en) 2007-05-30
JP5031567B2 (ja) 2012-09-19
US20080194636A1 (en) 2008-08-14
ZA200702041B (en) 2008-09-25
EP1789079B1 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
SG155901A1 (en) Enzyme inhibitors and uses thereof
MXPA05013224A (es) Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
EA200870446A1 (ru) Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов мек
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
IN2012DN03824A (ja)
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
GEP20115302B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MXPA05005223A (es) Diaminotriazoles utiles como inhibidores de proteinas cinasas.
GB0402137D0 (en) Novel compounds
TW200621253A (en) 2-amido-thiazole-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EA201501088A1 (ru) Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
SE0201980D0 (sv) Novel compounds
WO2010067130A8 (en) P38 map kinase inhibitors
GB0402143D0 (en) Novel compounds
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο